Welcome to our dedicated page for MICROVISION SEC filings (Ticker: MVIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MICROVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MICROVISION's regulatory disclosures and financial reporting.
MICROVISION, INC. (MVIS) reported that its Chief Financial Officer, Christine Chambers, received a grant of 562,114 Restricted Stock Units on September 2, 2026. The RSUs convert into common stock on a unit-for-share basis without payment and are scheduled to vest in four equal annual installments from August 27, 2027 through August 27, 2030, contingent on continued service.
MICROVISION, INC. (MVIS) reported that Chief Commercial Officer Jeemyung Byun received a grant of 674,536 Restricted Stock Units (RSUs)unit-for-share basis without payment and are scheduled to vest in four equal annual installments on July 20, 2027, 2028, 2029, and 2030, contingent on continued service through each vesting date. No transactions were made under a Rule 10b5-1 trading plan.
MICROVISION, INC. (MVIS) reported that Chief Financial Officer Christine Chambers has filed an initial statement of beneficial ownership on Form 3. The filing lists her as an officer of the company and reports no equity transactions and no specific share holdings in this form.
MICROVISION, INC. (MVIS) director Jada Smith reported the vesting and conversion of 4,670 Restricted Stock Units into an equal number of shares of common stock on September 1, 2026. After this transaction, Smith directly holds 16,440 shares of MicroVision common stock.
The RSUs were granted on July 16, 2026 and are scheduled to vest in four equal quarterly installments until fully vested on the earlier of the first anniversary of the grant date or the day prior to MicroVision’s 2027 Annual Meeting of Stockholders, contingent on continued board service. No Rule 10b5-1 trading plan is reported.
MICROVISION, INC. (MVIS) director Robert Paul Carlile reported the vesting and settlement of restricted stock units into common stock. On September 1, 2026, 4,670 RSUs were converted on a unit-for-share basis into 4,670 shares of common stock at no cash cost, increasing his directly held common shares to 42,051. The corresponding RSU derivative position was reduced to zero. No Rule 10b5-1 trading plan is reported.
Footnotes state these RSUs are part of a grant made on July 16, 2026 that is scheduled to vest in four equal quarterly installments until fully vested on the earlier of the first anniversary of the grant date or the day prior to MicroVision’s 2027 Annual Meeting of Stockholders, with the original grant of 280,152 RSUs on a pre-split basis equating to 18,677 RSUs on a post-split basis.
MICROVISION, INC. (MVIS) director Jeffrey A. Herbst reported the vesting and conversion of 4,670 Restricted Stock Units into the same number of shares of common stock on September 1, 2026, on a unit-for-share basis. Following this RSU distribution, Herbst directly holds 23,398 shares of MicroVision common stock. The RSUs are part of a grant of 18,677 post-split RSUs scheduled to vest in four equal quarterly installments through around the first anniversary of the July 16, 2026 grant date, assuming continued board service, and no Rule 10b5-1 trading plan is reported.
MICROVISION, INC. (MVIS) director Laura J. Peterson reported the vesting and settlement of restricted stock units into common shares. On September 1, 2026, 4,670 RSUs were exercised on a unit-for-share basis and distributed as 4,670 shares of common stock without payment. Following this distribution, Peterson holds 11,977 shares of common stock directly, and the specific RSU award reported in this filing now shows no remaining derivative balance. No Rule 10b5-1 trading plan is reported.
MICROVISION, INC. (MVIS) director Peter Schabert reported the vesting and exercise of 4,670 Restricted Stock Units into an equal number of shares of common stock on September 1, 2026. The RSUs converted to common stock on a unit-for-share basis without payment, bringing his direct common stock holdings to 15,902 shares. No Rule 10b5-1 trading plan is reported for these transactions.
MicroVision, Inc. (MVIS) announced that it has regained compliance with Nasdaq’s continued listing requirements. On August 26, 2026, Nasdaq Listing Qualifications informed the company that it now complies with Listing Rule 5550(a)(2), which requires a minimum bid price of at least $1 per share. MicroVision had previously received a noncompliance notice on January 12, 2026, but Nasdaq has now stated that the matter is closed.
MicroVision, Inc. completed a registered public offering of 6,800,000 shares of common stock together with warrants to purchase 6,800,000 shares. The securities were sold as units at a combined offering price of $2.50 per share and accompanying warrant, generating gross proceeds of $17.0 million and net proceeds of approximately $15.6 million after fees and expenses, excluding any future warrant exercises.
The warrants are immediately exercisable at $2.50 per share and remain exercisable for five years from closing. WestPark Capital, Inc. acted as sole placement agent on a reasonable best efforts basis, receiving a 6.5% cash commission and $115,000 in expense reimbursement. MicroVision plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.
For 45 days after closing, the company agreed not to issue additional common equity or price-reset securities (with limited exceptions), and not to make additional repayments on its senior secured convertible notes maturing March 1, 2028.